(Q44089731)

29 November 2017

title

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers (English)

1 reference

29 November 2017

1 reference

Christine Falcoz

1

1 reference

29 November 2017

Julian M Jenkins

2

1 reference

29 November 2017

Carole Bye

3

1 reference

29 November 2017

Timothy C Hardman

4

1 reference

29 November 2017

Kathy B Kenney

5

1 reference

29 November 2017

Scott Studenberg

6

1 reference

29 November 2017

H Fuder

7

1 reference

29 November 2017

William T Prince

8

1 reference

29 November 2017

publication date

1 August 2002

1 reference

The Journal of Clinical Pharmacology

29 November 2017

published in

1 reference

29 November 2017

volume

42

1 reference

29 November 2017

issue

8

1 reference

29 November 2017

page(s)

887-898

1 reference

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

Cost effectiveness of once-daily oral antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F009127002401102803

10.1177/009127002401102803

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference